uniQure stock price dropped another 12.86% after the FDA rejected the trial data, down a total of 56% this year.

LootboxPhobia · 2026-03-03T23:28:03+00:00

uniQure stock plummeted after the FDA rejected its data for the Huntington's disease gene therapy, dropping 12.86% to $9.15 in pre-market trading on Tuesday, following a 45% decline on Monday. The FDA deemed the trial data insufficient and recommended new studies.

LootboxPhobia

2026-03-03 23:28:03

Abstract generation in progress

Investing.com – uniQure (NASDAQ:QURE) stock fell 12.86% pre-market on Tuesday to $9.15, after the U.S. Food and Drug Administration rejected the company’s trial data for Huntington’s disease gene therapy.

The stock had already plummeted 45% during Monday’s trading session.

On Monday, the FDA notified the drug developer that its early to mid-stage trial data for Huntington’s disease gene therapy was insufficient to support a marketing application.

The FDA recommended conducting a new study, randomly assigning patients to receive either the gene therapy or a placebo surgery.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes